Opinion change, from Reduce to Buy (Neovacs)
information fournie par AlphaValue 06/01/2016 à 17:17
OPINION CHANGE
CHANGEMENT D’OPINION
Buy vs Reduce
CHANGEMENT D’EPS
2015 : € -0.13 vs -0.13
2016 : € -0.25 vs -0.27 ns
Due to the new funding from Bpi France (€5m), we have decreased the financial expenses, leading to a slight increase in EPS 2016.
CHANGEMENT DE NAV
€ 1.87 vs 1.34 +39.8%
We have revised up the valuation for IFN Kinoide after the partnership signed in late 2015, with a positive impact from 2016. This partnership strengthens the likelihood of success in Lupus and dermatomyositis, even if the results of the phase IIb is expected in late H1 17.